BCL-XL is upregulated in JAK2-driven MPNs and contributes to apoptosis resistance.
Pharmacologic inhibition of BCL-XL with ABT-263 induces mitochondrial apoptosis in PMF-derived MSCs.
Combined inhibition of BCL-XL and JAK2 shows synergistic antifibrotic and pro-apoptotic effects.
MSCs from MPN patients exhibit a myofibroblast-like phenotype with increased α-SMA and FN expression.
TGF-β activates SMAD3 and STAT3 signaling in MSCs, indicating a role in fibrotic activation.
TGF-β's role in MSC activation and fibrosis should be highlighted.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Monitor for disease progression to advanced myelofibrosis or secondary acute myeloid leukemia.
Monitor for on-target thrombocytopenia associated with BCL-XL inhibition.
Risks
Patient & Prescribing Data
Navitoclax (ABT-263) shows efficacy in reducing spleen enlargement and symptom burden when combined with ruxolitinib, particularly in patients with advanced MPNs.
Clinical Best Practices
Consider dual targeting of BCL-XL and JAK2 for advanced MPN management.
Evaluate the fibrotic phenotype of MSCs in MPN patients for tailored therapeutic strategies.
Implement monitoring strategies for patients on dual therapy.
